NCT04817657No Longer Available不适用

COVID Vaccine VAC31518 Pre-approval Access Study

Janssen Research & Development, LLC0 个研究点开始时间: 2021年3月26日最近更新: 2021年3月26日

研究概览

简要总结

The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S) vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection. This PAA program may be considered to protect participants against a serious/life-threatening diseases or conditions, where there are no alternative treatments available.

研究设计

研究类型: Expanded Access

入排标准

入选标准

未提供

排除标准

未提供

研究者

发起方

Janssen Research & Development, LLC

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult ParticipantsCOVID-19, SARS-CoV-2

NCT05932641AstraZeneca24

已完成

不适用

Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19 Vaccination Program Among Populations in Very Precarious SituationsCOVID-19

NCT05075941Epicentre3,811

已完成

1 期

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) VaccineCOVID-19 Vaccine

NCT05656508Laboratorio Pablo Cassara S.R.L.80

Unknown

3 期

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular LymphomaNon-Hodgkins Lymphoma

NCT00091676Biovest International629

已完成

1 期

A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)Healthy

NCT06630117Merck Sharp & Dohme LLC245